Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00564226 | SSR240600C Treatment in Women With Overactive Bladder | PHASE2 | COMPLETED | 345 | — | — | Nov 1, 2007 | Feb 1, 2009 | May 26, 2016 | 7 | United States, Canada +5 |
| NCT00174798 | MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence. | PHASE2 | COMPLETED | 118 | — | — | May 1, 2005 | May 1, 2006 | Feb 2, 2012 | 22 | United States |
| Arm | Type | Description |
|---|---|---|
| SSR240600C Dose Level 1 | EXPERIMENTAL | - |
| SSR240600C Dose Level 2 | EXPERIMENTAL | - |
| SSR240600C Dose Level 3 | EXPERIMENTAL | dose level 3 |
| Tolterodine | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| SSR240600C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SSR240600C | DRUG | oral administration |
| tolterodine | DRUG | oral administration |
| placebo | DRUG | oral administration |
Inclusion Criteria: * Diagnosis of overactive bladder Exclusion Criteria: * Stress incontinence or mixed incontinence where stress incontinence is the predominant component based on prior history * Urinary incontinence due to cause other than detrusor overactivity (eg, overflow incontinence) * Cu...